Journal of Oncology Pharmacy Practice最新文献

{"title":"Chronic cannabis use in breast cancer survivors: A questionnaire study of Israeli patients.","authors":"Or Duchin, Bella Smolin, Hedva Sheinman, Natali Katsman, Shaked Ben Porat, Igal Louria-Hayon, Ayelet Shai","doi":"10.1177/10781552251340329","DOIUrl":"https://doi.org/10.1177/10781552251340329","url":null,"abstract":"<p><p>IntroductionAs many as 90% of BC survivors suffer from long term sequelae, and many use or used cannabis during or after treatment to alleviate symptoms. Little is known about the effects of chronic cannabis use in this population. We aimed to study the patterns and effects of chronic cannabis use in BC survivors.Materials and methodsthis is a single center cohort study. Participants were patients aged 30-75, diagnosed with stage 1-3 BC and prescribed medical cannabis. Patients were included if they completed chemotherapy at least 6 months before study entry and did not experience disease recurrence during follow up. Patients were interviewed over the phone regarding the patterns and effects of cannabis use.ResultsTwenty-one patients were included. At the time of interview all patients increased their cannabis dose from 20 grams per month to an average of 47.6 grams per month. The positive effects reported were improved mood (76%), sleep (62%), pain (52%), neuropathy (29%) and appetite (5%). Adverse effects were increased appetite (10%), sleepiness (10%), cognitive adverse effects (10%), nausea (5%), mood adverse effects (5%) and gait problems (5%). Six patient (29%) reported themselves as being addicted to cannabis.ConclusionIn this cohort, long term cannabis use was associated with adverse effects, dose increments and risk of addiction. Further study is needed to better understand the safety of chronic cannabis use in BC survivors.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251340329"},"PeriodicalIF":1.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world efficacy and tolerability of axitinib + pembrolizumab in the treatment of renal cell carcinoma.","authors":"Kyle Ritter, Malgorzata Strojny, Jane McCullough, Jenn Law","doi":"10.1177/10781552251331576","DOIUrl":"https://doi.org/10.1177/10781552251331576","url":null,"abstract":"<p><p>Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs) is standard of care for metastatic renal cell carcinoma (mRCC); however, no head-to-head trials have compared FDA-approved regimens. This project aims to provide real-world data on the safety and efficacy of axitinib + pembrolizumab in the treatment of mRCC and describe management of common treatment-related adverse events. This is a retrospective, observational, quality improvement project conducted at the Robert H Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Illinois. Patients 18 years of age or older with stage IV RCC who received axitinib + pembrolizumab between April 2019 and February 2024 were included. Endpoints included progression-free survival (PFS), overall survival (OS), duration of treatment, subsequent therapies, and safety outcomes. Thirty-one patients received axitinib + pembrolizumab for mRCC. With a median follow-up time of 22.6 months, PFS was 37.4 months and OS was not reached. Ninety-four percent of patients experienced a treatment-related adverse event with 32.3% classified as grade 3 or higher. Fifty two percent of patients required axitinib dose reductions, 70.9% had at least one axitinib dose held, and 70.9% had at least one pembrolizumab dose held. Patients with axitinib dose reductions demonstrated improved OS at one year (92.9% vs. 80%). This retrospective study corroborates the findings of the KEYNOTE-426 trial and further demonstrates the effectiveness of axitinib + pembrolizumab combination therapy in the treatment of mRCC. Dose reductions and holds do not appear to impact treatment efficacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251331576"},"PeriodicalIF":1.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to current medicines in the treatment of Turkish melanoma patients.","authors":"Faruk Tas, Zubeyde Yolcu","doi":"10.1177/10781552251340008","DOIUrl":"https://doi.org/10.1177/10781552251340008","url":null,"abstract":"<p><p>Although the incidence of melanoma is increasing every year, the modern treatment modalities provided in recent years have led to significant gains in survival. However, there are difficulties in access to medicines in our country as well as in the world, especially due to the cost of medicines. In this study, we investigated to determine the access to drugs in our country. Our study was conducted using January 2025 data based on the Health Practice Circular of the Social Security Institution. In metastatic melanoma patients, BRAF/MEK inhibitor agents, vemurafenib-cobimetinib and dabrafenib-trametinib combination therapies, have been registered and reimbursed in the first-line treatment choice of the disease. Among immunotherapy drugs, ipilimumab and nivolumab as single agents have long been registered and reimbursed for the treatment of relapsed disease after chemotherapy, while pembrolizumab is still registered but not reimbursed. Ipilimumab-nivolumab is registered but still not imbursed. Talimogen laherparepvec and tebentafusp are still not registered. The dabrafenib-trametinib combination has been registered and reimbursed for the adjuvant treatment of stage 3. However, although both nivolumab and pembrolizumab are licensed as single agents, they are not covered by reimbursement. In the adjuvant treatment of stage 2 (2B/C) disease, pembrolizumab is licensed but not reimbursed, while nivolumab is not licensed. In conclusion, in our country, as in other parts of the world, there are difficulties and limitations in accessing the current treatment of melanoma. The significant survival benefits achieved with modern treatment of the disease are unfortunately hampered by difficulties in accessing treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251340008"},"PeriodicalIF":1.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel decision tree for performing risk assessments of biologics in a health-system setting.","authors":"Zoe Ngo, Scott Mayeda, Stacey Yu, Mark Danek, Austin Wang, Elyse A MacDonald, Ee Vonn Yong, Janjri Desai","doi":"10.1177/10781552251338047","DOIUrl":"https://doi.org/10.1177/10781552251338047","url":null,"abstract":"<p><p>ObjectiveTo develop and implement a biological drug risk assessment decision tree that expands upon National Institute for Occupational Safety and Health (NIOSH) risk assessment evaluation procedures with the addition of molecular property parameters for exposure assessment.Data SourcesA literature review was performed using PubMed^® (Keywords: peptide, protein, biologics, occupational exposure, risk assessment, molecular weight, molecular weight and penetration, skin, nasal absorption, ocular absorption, inhalation bioavailability. Period: 1991 to 2024).Data SummaryA thorough literature review showed a wide range of molecular weight cut-offs for absorption of biological drugs through various pathways (dermal, mucosal, inhalation). Large molecules greater than 1000 Daltons in size were found to have little to no bioavailability through these pathways, hence this weight was established as the size threshold within the risk assessment decision tree. Practical application of this decision tree by the investigational drug service in a large academic institution led to the reclassification of 89% of medications with previous hazardous designation.ConclusionsIn response to the increasing prevalence of biological drugs and limited guidelines on occupational handling, a protein-based biologics risk assessment decision tree, expanding on existing NIOSH evaluation procedures and incorporating molecular weight parameters was developed. Adoption of a risk assessment tool can help standardize and streamline biologics handling practice, which can improve operational efficiency without compromising staff safety.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251338047"},"PeriodicalIF":1.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the relationship between letermovir prophylaxis and medication regimen complexity Index over time in allogeneic hematopoietic stem cell transplant patients.","authors":"Anthony Quach, Nimish Patel, Hailey Hirata, Annie Bui, Julie Trinh, Shreya Bahl, Ila M Saunders","doi":"10.1177/10781552251330276","DOIUrl":"https://doi.org/10.1177/10781552251330276","url":null,"abstract":"<p><p>BackgroundThe medication regimen complexity index (MRCI) quantifies patient-level regimen complexity, and higher scores are associated with adverse clinical outcomes. Characterization of regimens using the MRCI for allogeneic hematopoietic cell transplant (allo-HCT) recipients remains unexplored. Regimens may include letermovir which is used for cytomegalovirus prophylaxis and may prevent the need for addition of complex preemptive therapies. However, quantification of complexity in patients receiving letermovir has not been described.ObjectiveThis study aimed to compare MRCI scores over a one-year period in allo-HCT recipients who received letermovir prophylaxis versus those who did not.MethodsA retrospective analysis included adults who underwent allo-HCT from January 1, 2016 to October 31, 2021. MRCI scores were calculated at admission, discharge, day +100, 6 months, and 1-year post-transplant.ResultsA total of 218 patients were included, with 67 receiving letermovir and 151 not receiving letermovir. Median MRCI scores were comparable at discharge post allo-HCT (23 [10-39] vs 22 [12-37], <i>p </i>= 0.97). However, at day +100, patients in the letermovir group exhibited significantly higher median scores compared to the non-letermovir group (59 [46-74] vs 50 [37-67], <i>p </i>= 0.009). By 1-year post allo-HCT, no significant difference in scores was observed between groups (47 [30-68] vs 41 [27-61], <i>p </i>= 0.12).Conclusion and RelevanceThis study revealed increased MRCI scores up to one year after transplantation in allo-HCT recipients receiving letermovir. The nonrandomized study design and potential patient differences between groups complicate the interpretation of the findings. Future analyses should aim to account for these differences.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330276"},"PeriodicalIF":1.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of drug interactions in oncology: Prevalence, risk factors and severity in a tertiary care hospital.","authors":"Shreya Kolte, Srinivasa Chelluri, Priti Dhande","doi":"10.1177/10781552251338769","DOIUrl":"https://doi.org/10.1177/10781552251338769","url":null,"abstract":"<p><p>BackgroundPatients ongoing cytotoxic chemotherapy concomitantly receive drugs for prevention of adverse effects as well as treatment for comorbidity. Exposure to such large number of drugs increases the chances of drug-drug interactions. This study was planned to determine the potential drug interactions and risk factors associated with them, in cancer patients of a tertiary care teaching hospital.MethodologyProspective, observational study conducted in the adult and pediatric oncology units. Data of medications received by each patient entered in UpToDate software to get the information about potential drug interactions (pDDI). Any observed outcome due to the drug interaction was noted down along with its management. Welch's independent samples t-test was conducted to identify quantitative factors that had a significant impact on observed Drug-Drug Interactions (oDDI). Pearson's correlation coefficient was calculated for all quantitative variables.ResultsOut of 110 patients, pDDI were found in 93.6% of them and actually occurred in 49.1% of these patients. Most of the pDDI were between the co-administered drugs (67.1%) in whom supportive medications were given or patient monitored. Significant association was found between the number of drug-drug interactions (DDIs) and age of the patient (p = 0.020), total number of drugs used (p < 0.001), number of drugs for comorbidities (p = 0.024), and number of co-administered medications (p < 0.001).ConclusionHigh prevalence of drug interactions among cancer patients indicates the need to develop protocols for monitoring and effective communication between healthcare providers for safe and effective care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251338769"},"PeriodicalIF":1.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: A prospective phase iv study.","authors":"Fengrong Wang, Zhen Cai, Dehui Zou, Wenming Chen, Yongping Song, Chengcheng Fu, Jiong Hu, Ting Yang, Xinchuan Chen, Jinsong Yan, Kaiyan Liu","doi":"10.1177/10781552251336172","DOIUrl":"https://doi.org/10.1177/10781552251336172","url":null,"abstract":"<p><p>BackgroundMelphalan formulated with modified cyclodextrin (β-cyclodextrin sulfobutyl ether sodium [BSES]) is widely used before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) because of its favorable solubility and stability versus conventional melphalan, but the efficacy and safety data on Chinese patients with MM who subsequently underwent ASCT are still limited.MethodsIn this prospective, open-label, non-randomized, interventional study, a total of 67 MM patients who were eligible for ASCT were enrolled and assigned to receive 200 mg/m² of Melphalan in two divided doses of 100 mg/m² on Days -3 and -2 before ASCT on Day 0. We evaluated the efficacy, safety and pharmacokinetics (PK) of a prolonged infusion of high-dose BSES-melphalan as the conditioning treatment in the patients.ResultsOverall, 67 patients received melphalan with the median infusion time of 136 min. All patients achieved myeloablation with a median time of 5 days. Median time to neutrophil and platelet engraftments was 11 and 12 days after ASCT, respectively. Within the 65 evaluable patients, 18 patients (27.7%) achieved stringent complete response, 21 (32.3%) achieved complete response, 18 (27.7%) achieved very good partial response, and 3 (4.6%) achieved partial response. No treatment-related mortality (TRM) or adverse events leading to study withdrawal were identified. Prolonged infusion resulted in a lower C_max but comparable AUCs.ConclusionsHigh-dose BSES-melphalan as a conditioning medicine is effective and safe in Chinese patients with MM before ASCT. Prolonging infusion duration may improve the safety without compromising efficacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251336172"},"PeriodicalIF":1.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome.","authors":"Derek Tai, Daniel Park, Priscilla Soria, Pranati Shah, Kendall Wick, So Young Son, Won Jin Jeon, Kum-Ja Lee, Mojtaba Akhtari","doi":"10.1177/10781552251332278","DOIUrl":"https://doi.org/10.1177/10781552251332278","url":null,"abstract":"<p><p>Inotuzumab (InO) is an anti-CD22 immunoconjugate for patients with relapsed or refractory CD22 positive B-cell acute lymphoblastic leukemia (B-ALL). Liver toxicity is a recognized side effect of InO, including sinusoidal obstruction syndrome (SOS), but is not fully understood. This study describes a new aspect of InO-induced hepatotoxicity by outlining six patients who developed abnormal liver function tests (LFTs) and thrombocytopenia, with liver biopsies showing sinusoidal congestion without evidence of SOS. Liver biopsies were obtained from all six patients and LFTs were monitored before initiating InO treatment, during treatment, and after discontinuing treatment. All six patients experienced abnormal LFTs at a median of 15 days after the last dose of InO and improvement in LFTs at a median of 17 days after discontinuing InO. Initial baseline AST, ALT, ALP, and total bilirubin values prior to InO therapy ranged from 10-45 U/L, 10-45 U/L, 60-207 U/L, and 0.2-0.9 mg/dL respectively and increased up to 2 to 4 times the upper limit of normal after completing varying cycles of InO with hepatotoxicity grades ranging from 1-2. LFTs returned to 1 to 1.5 times the upper limit of normal after discontinuing InO. The patients' liver biopsies all demonstrated different levels of hepatic sinusoidal congestion (HSC) without evidence of SOS. This study provides new evidence describing HSC, where we hypothesize that InO induced hepatotoxicity are due to calicheamicin. We propose a new clinical entity called \"calicheamicin syndrome\" with its quadriad components: History of using InO or GO, elevated LFTs, thrombocytopenia, and abnormal liver imaging.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251332278"},"PeriodicalIF":1.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease.","authors":"Julie Lyon Boucher, Katie Lynn Konieczny, Blerina Mukallari, Eva Yifang Pan, Annette Hood, Mara Hofherr","doi":"10.1177/10781552251333650","DOIUrl":"https://doi.org/10.1177/10781552251333650","url":null,"abstract":"<p><p>IntroductionPatients with residual invasive carcinoma after neoadjuvant chemotherapy (NACT) for early-stage breast cancer have poor prognoses. The primary objective of this study was to assess the safety and tolerability of adjuvant combination regimens in patients with residual disease after KEYNOTE-522 NACT and surgery.MethodsPatients ≥ 18 years old with triple-negative or hormone-receptor low positive early-stage breast cancer were included if treated with KEYNOTE-522 NACT (modified to dose-dense doxorubicin plus cyclophosphamide (ddAC) in most patients). After definitive surgery, patients were assessed for residual disease and whether they received adjuvant capecitabine or a poly ADP ribose polymerase (PARP) inhibitor concurrently with pembrolizumab or sequentially after pembrolizumab. Adverse effects and dose modifications were collected.ResultsTwenty-two patients received concurrent treatment and eight received sequential treatment. Higher rates of toxicity occurred when two adjuvant agents were administered concurrently compared to sequentially (p-value = 0.166). The concurrent group also had more capecitabine dose adjustments (50% vs. 37.5%), doses held (36.4% vs. 25%) and discontinuations (9.1% vs. 0%) as well as pembrolizumab discontinuations (13.67% vs. 0%). The pathologic complete response (pCR) rates were higher with the use of ddAC than with every-3-weeks doxorubicin plus cyclophosphamide (AC) administered in KEYNOTE-522 (84.7% vs. 64.8%).ConclusionConcurrent therapy with pembrolizumab and capecitabine or olaparib trended towards demonstrating more toxicities than sequential therapy, though not statistically significant. However, concurrent therapy can be completed with dose adjustments or holds per patient tolerability. Additionally, our findings suggest modifying NACT KEYNOTE-522 to ddAC may improve response rates over traditional NACT KEYNOTE-522.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251333650"},"PeriodicalIF":1.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of medicinal plants by cancer patients receiving chemotherapy: A cross-sectional study at a referral oncology hospital in Morocco.","authors":"Aichetou Bouh, Slimane Mehdad, Nouriya El Ghoulam, Daoud Daoudi, Ahmed Oubaasri, Fatima Zahra El Mskini, Asmae Labyad, Hinde Iraqi, Souad Benaich, Rachida Hassikou, Hassan Errihani, Saber Boutayeb","doi":"10.1177/10781552251331920","DOIUrl":"https://doi.org/10.1177/10781552251331920","url":null,"abstract":"<p><p>Background and aimThe high cost of cancer treatment and adverse side effects of drug therapy remain major health issues worldwide. Medicinal plants (MP) can be used to promote new, safe, and effective anticancer medications. This study aimed to estimate the prevalence of MP use among cancer patients, investigate its association with sociodemographic and clinical factors, and provide available information about the species used.Materials and methodsThis was a cross-sectional study among 508 patients undergoing chemotherapy. Sociodemographic data and information on MPs used in cancer treatment were collected using face-to-face interviews and a questionnaire. Clinical data were obtained from the hospital database. Ethnobotanical indices, including relative citation frequency, informed consensus factor, and fidelity level, were determined for data analysis.Results43.2% of patients used MPs. Of these, 66.3% did not disclose information about MPs to their physicians, 54% experienced improvements, and 6% reported undesirable side effects associated with using MPs. There was a significant association of MPs use with disease duration (<i>P </i>= 0.037) and cancer type (<i>P </i>< 0.001). 27 plant species belonging to 17 families were identified, with Lamiaceae, Apiaceae, and Fabaceae being the most common. The most used species were <i>Origanum compactum benth</i>., <i>Marrubium vulgare</i> L., <i>Trigonella foenum-graecum</i> L., <i>Aloysia citriodora</i>, and <i>Rosmarinus officinalis</i> L.ConclusionThis study showed a high prevalence of MPs use among patients undergoing chemotherapy. Although further studies are needed to investigate the efficacy and safety of commonly used species, our findings may be used to inform evidence-based guidelines, promote communication between cancer patients and healthcare providers, and develop new medicinal plants.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251331920"},"PeriodicalIF":1.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}